Zug, Switzerland, March 7, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the full year 2016 on Tuesday, March 14, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (1:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-3488 (USA) or +1-646-254-3372 (International), and enter passcode 7503630. A live webcast of the conference call can be accessed in the Investors section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



